AMI Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

AMI Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$973K	Sell	37,121 -13,742	-27%	-$320K	0.06%	61
2026 Q1	$1.2M	Buy	50,863 +1,601	+3%	+$40.9K	0.08%	45
2025 Q4	$1.43M	Sell	49,262 -46,829	-49%	-$1.2M	0.08%	46
2025 Q3	$1.81M	Sell	96,091 -17,791	-16%	-$281K	0.1%	39
2025 Q2	$1.6M	Sell	113,882 -94,839	-45%	-$1.33M	0.09%	39
2025 Q1	$3.26M	Sell	208,721 -7,237	-3%	-$102K	0.19%	39
2024 Q4	$3.01M	Sell	215,958 -7,723	-3%	-$84.6K	0.16%	39
2024 Q3	$2.08M	Buy	223,681 +59,487	+36%	+$587K	0.11%	42
2024 Q2	$1.53M	Sell	164,194 -181,045	-52%	-$1.64M	0.08%	52
2024 Q1	$3.42M	Buy	+345,239	New	+$2.58M	0.17%	57

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AMI Asset Management's ARQT Position: Q2 2026 in Review

AMI Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 27% in Q2 2026, selling an estimated $320K and leaving 37,121 shares worth $973K. The position accounts for 0.06% of the portfolio, ranked #61.

AMI Asset Management first reported a position in ARQT in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.42M in Q1 2024. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

AMI Asset Management held 37,121 shares of Arcutis Biotherapeutics worth $973K as of Q2 2026.
AMI Asset Management sold 13,742 Arcutis Biotherapeutics shares in Q2 2026, an estimated $320K.
Arcutis Biotherapeutics made up 0.06% of AMI Asset Management's portfolio in Q2 2026, its #61 holding.
AMI Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
AMI Asset Management's Arcutis Biotherapeutics position peaked at $3.42M in Q1 2024.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on AMI Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.